Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.
Aim(s): We hypothesize that capecitabine-temozolomide (CAPTEM) could be a valid option in this setting.
Materials and methods: We retrospectively analyzed the outcome of NEN patients treated with CAPTEM in 12 sites in Spain between June/2008 and October/2015.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
Crespo G H
, Lopez C
, Jimenez-Fonseca P
, Matos I
, Capdevila J
, Custodio A
, Carmona-Bayonas A
, Alonso T
, Gajate P
, Aller J
, Navarro M
, Sevilla I
, Alonso V
, Nieto B
, Barriuso J
To read results and conclusion, please login ...
Further abstracts you may be interested in